Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) CEO Douglas Fambrough purchased 33,100 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Tuesday, November 15th. The stock was acquired at an average cost of $3.71 per share, with a total value of $122,801.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded up 17.58% during midday trading on Thursday, reaching $4.08. The company’s stock had a trading volume of 572,451 shares. Dicerna Pharmaceuticals Inc. has a 52 week low of $2.69 and a 52 week high of $15.93. The company’s 50-day moving average is $4.04 and its 200 day moving average is $3.63. The firm’s market capitalization is $84.67 billion.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.17. The company had revenue of $162 million for the quarter. Analysts expect that Dicerna Pharmaceuticals Inc. will post ($2.95) earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its position in Dicerna Pharmaceuticals by 0.4% in the second quarter. FMR LLC now owns 3,108,916 shares of the biopharmaceutical company’s stock worth $9,327,000 after buying an additional 11,719 shares in the last quarter. Oxford Asset Management raised its position in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 149,560 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Dicerna Pharmaceuticals during the first quarter worth about $343,000. Paloma Partners Management Co bought a new position in Dicerna Pharmaceuticals during the second quarter worth about $183,000. Finally, A.R.T. Advisors LLC bought a new position in Dicerna Pharmaceuticals during the second quarter worth about $170,000. 62.34% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on DRNA shares. Zacks Investment Research raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a report on Tuesday, October 4th. Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Wednesday, September 28th. Leerink Swann reiterated a “buy” rating and set a $8.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Tuesday, November 8th. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Friday, August 5th. Finally, Chardan Capital cut their price objective on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a research note on Monday, August 15th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $9.85.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.